Cargando…

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries

SIMPLE SUMMARY: Recent studies have mostly focused on the treatment of advanced mycosis fungoides and Sézary syndrome and less on the treatment of relapsed or refractory (R/R) cases of cutaneous T-cell lymphoma (CTCL). There is also a paucity of data on the treatment and outcomes of primary cutaneou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assaf, Chalid, Waser, Nathalie, Bagot, Martine, He, Mary, Li, Tina, Dalal, Mehul, Gavini, Francois, Trinchese, Fabrizio, Zomas, Athanasios, Little, Meredith, Pimpinelli, Nicola, Ortiz-Romero, Pablo L., Illidge, Timothy M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750476/ https://www.ncbi.nlm.nih.gov/pubmed/35008309 http://dx.doi.org/10.3390/cancers14010145

Ejemplares similares

First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
por: Kaloyannidis, Panayotis, et al.
Publicado: (2019)

The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)
por: Gantchev, Jennifer, et al.
Publicado: (2019)

28665 Cutaneous T-cell lymphoma (CTCL) outcomes during COVID-19
por: Garcia-Saleem, Tiffany J., et al.
Publicado: (2021)

The Skin Microbiome in Cutaneous T-Cell Lymphomas (CTCL)—A Narrative Review
por: Łyko, Magdalena, et al.
Publicado: (2022)

JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)
por: Vadivel, Chella Krishna, et al.
Publicado: (2021)

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)
por: Kołkowski, Karol, et al.
Publicado: (2021)

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
por: Nicolay, Jan P., et al.
Publicado: (2023)

A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL)
por: Tsang, Matthew, et al.
Publicado: (2018)

Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL)
por: Ghazawi, Feras M., et al.
Publicado: (2019)

Cutaneous T-cell lymphoma (CTCL) exacerbation after viral vector COVID-19 vaccination
por: Panou, Evdoxia, et al.
Publicado: (2021)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel
por: Denis, Daphné, et al.
Publicado: (2019)

International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
por: Geskin, Larisa J, et al.
Publicado: (2021)

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib
por: KieΔling, Michael K., et al.
Publicado: (2017)

Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL
por: Chi, Cheng, et al.
Publicado: (2022)

Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL
por: Khan, Shaheer, et al.
Publicado: (2019)

PB2396: HDACI COMBINED WITH LB100 PROMOTES THE OCCURRENCE OF FERROZOSIS IN CTCL
por: Shi, Wenyu
Publicado: (2023)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo
por: Mazuz, Moran, et al.
Publicado: (2020)

TMEM244 Is a Long Non-Coding RNA Necessary for CTCL Cell Growth
por: Rassek, Karolina, et al.
Publicado: (2023)

Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
por: Uckun, Fatih M., et al.
Publicado: (2018)

Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155
por: Litvinov, Ivan V, et al.
Publicado: (2013)

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description
por: D’Agostino, Paolo, et al.
Publicado: (2020)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Illidge, T., et al.
Publicado: (2022)

New Targeted Treatments for Cutaneous T-cell Lymphomas
por: Bagot, Martine
Publicado: (2017)

Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
por: Marzec, Michal, et al.
Publicado: (2011)

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations
por: Crimp, Caitlin, et al.
Publicado: (2022)

Evaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides).
por: Thayu, M., et al.
Publicado: (1999)

Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients
por: Bagdonaite, Ieva, et al.
Publicado: (2015)

Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
Publicado: (2020)

Targeting the non‐ATP‐binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T‐cell lymphoma (CTCL)
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
por: Wang, Zhaohui, et al.
Publicado: (2023)

Cutaneous Vasculitis in a Patient With COVID-19
por: Kösters, Katrin, et al.
Publicado: (2020)

Refractory ascites—the contemporary view on pathogenesis and therapy
por: Kasztelan-Szczerbinska, Beata, et al.
Publicado: (2019)

P1161: THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.
por: Brink, Mirian, et al.
Publicado: (2023)

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2018)

Key Role of Reactive Oxygen Species (ROS) in Indirubin Derivative-Induced Cell Death in Cutaneous T-Cell Lymphoma Cells
por: Soltan, Marwa Y., et al.
Publicado: (2019)

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
por: Suri, Ajit, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7v5sp19kf4oln13ioo0aideafu